Trial Profile
A Two-part, Phase I, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Tolerability and Immunogenicity of a Dose Range og Group B Streptococcus Vaccine in Healthy Female Volunteers Aged 18 to 40.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Jul 2021
Price :
$35
*
At a glance
- Drugs GBS NN (Primary) ; Aluminium hydroxide
- Indications Streptococcal infections
- Focus Adverse reactions
- Acronyms NeoStrep
- Sponsors Minervax
- 29 Jun 2021 Results published in the Vaccine
- 01 Nov 2017 Planned End Date changed from 1 Mar 2018 to 21 Apr 2017.
- 01 Nov 2017 Planned primary completion date changed from 1 Mar 2016 to 12 Apr 2017.